JIC
TNDM icon

Joel Isaacson & Co’s Tandem Diabetes Care TNDM Stock Holding History

Joel Isaacson & Co’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,000
Closed -$300K – 243
2018
Q3 		$300K Buy
+7,000
New +$244K 0.05% 161

Other funds holding TNDM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Joel Isaacson & Co's TNDM Position: Q4 2018 in Review

Joel Isaacson & Co sold out of Tandem Diabetes Care (TNDM) in Q4 2018, closing a stake of 7,000 shares — an estimated $300K sold.

Joel Isaacson & Co first reported a position in TNDM in Q3 2018 and held it in 1 quarter. The position peaked at $300K in Q3 2018. 200 funds tracked by Wall St. Rank hold TNDM as of Q4 2018.

  • Joel Isaacson & Co reported no remaining Tandem Diabetes Care position as of Q4 2018 after selling out during the quarter.
  • Joel Isaacson & Co sold 7,000 Tandem Diabetes Care shares in Q4 2018, an estimated $300K.
  • Joel Isaacson & Co first reported a position in Tandem Diabetes Care in Q3 2018 and held it in 1 quarter.
  • Joel Isaacson & Co's Tandem Diabetes Care position peaked at $300K in Q3 2018.
  • 200 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2018.

Based on Joel Isaacson & Co's 13F filing for Q4 2018, filed 18 Jan 2019.